Eibhlin Conneally

Dublin, L, Ireland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications

A window of opportunity: tear cytokine profiles in chronic ocular graft-versus-host disease.

A window of opportunity: tear cytokine profiles in chronic ocular graft-versus-host disease.

Journal: Eye (London, England)
Published: April 09, 2026

Pilot Study Comparing the In Vitro Response of Circulating Monocytes to Aspergillus fumigatus Swollen Conidia in Patients with Chronic Graft-Versus-Host Disease and Healthy Volunteers.

Pilot Study Comparing the In Vitro Response of Circulating Monocytes to Aspergillus fumigatus Swollen Conidia in Patients with Chronic Graft-Versus-Host Disease and Healthy Volunteers.

Journal: Journal of fungi (Basel, Switzerland)
Published: February 07, 2025

Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced-Intensity Fludarabine, Busulfan and Anti-T-Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy.

Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced-Intensity Fludarabine, Busulfan and Anti-T-Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy.

Journal: European journal of haematology
Published: January 07, 2025

Molecular diagnostic criteria of myeloproliferative neoplasms.

Molecular diagnostic criteria of myeloproliferative neoplasms.

Journal: Expert review of molecular diagnostics
Published: November 24, 2023

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.

Journal: Leukemia
Published: May 30, 2023

Frequency and driver mutation diversity of concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm.

Frequency and driver mutation diversity of concomitant chronic myeloid leukemia and Philadelphia chromosome-negative myeloproliferative neoplasm.

Journal: International journal of hematology
Published: March 06, 2023

Seeing the unseen: Use of a modified OSDI questionnaire to accurately detect chronic ocular GVHD in a hematology clinic.

Seeing the unseen: Use of a modified OSDI questionnaire to accurately detect chronic ocular GVHD in a hematology clinic.

Journal: The ocular surface
Published: July 08, 2022

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.

Journal: HemaSphere
Published: March 14, 2022

Correction: Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Correction: Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Journal: Leukemia
Published: September 02, 2021

Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Journal: Leukemia
Published: March 25, 2021

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.

Journal: Leukemia
Published: January 25, 2021

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.

Journal: Leukemia
Published: November 17, 2020
Showing 1-12 of 47

Last Updated: 09/26/2026